Similarly, in the C1142 (KRAS G12V) PDX model, the combination of dasatinib and trametinib did not produce significantly greater tumor growth inhibition than did dasatinib or trametinib alone (S5 Fig). The gene discussed is KRAS; the disease is neoplasm.